title: [Chemotherapy for two patients with non-Hodgkin's lymphoma in hemodialysis].
abstract: There are few reports on chemotherapy of non-Hodgkin's lymphoma (NHL) in patients with chronic renal failure. Two long-term hemodialysis patients were treated for NHL with modified CHOP therapy. The plasma pharmacokinetics of adriamycin (ADR) and etoposide (VP-16) were investigated in these patients. In the first case, NHL was diagnosed in a 37-year-old male (diffuse pleomorphic, T cell type, stage I E). After 4 courses of chemotherapy, he achieved complete remission. The second case, was a 56-year-old male who was admitted to our hospital with melena and abdominal pain. A diagnosis of NHL (diffuse mixed, B cell type, stage III E) was made. Complete remission was achieved with 2 courses of chemotherapy. Levels of hematological and neurological toxicity were moderately severe but tolerable. Pharmacokinetics of ADR and VP-16 in these patients were similar to those in patients with normal renal function. These results suggested that ADR and VP-16 were effective drugs for hemodialysis patients with NHL.
authors.affiliation: First Department of Internal Medicine, St. Marianna University School of Medicine.
authors.forename: F
authors.initials: F
authors.lastname: Sano
authors.forename: M
authors.initials: M
authors.lastname: Koike
authors.forename: M
authors.initials: M
authors.lastname: Ishibashi
authors.forename: K
authors.initials: K
authors.lastname: Tuji
authors.forename: M
authors.initials: M
authors.lastname: Katoh
authors.forename: S
authors.initials: S
authors.lastname: Hasegawa
authors.forename: T
authors.initials: T
authors.lastname: Maeba
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Ohwada
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: M
authors.initials: M
authors.lastname: Ishida
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics; D005047:Etoposide / Q000493:pharmacokinetics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000493:pharmacokinetics; D012074:Remission Induction; D006435:Renal Dialysis / Q000009:adverse effects*; D014750:Vincristine / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone